Mesalazine for diverticular disease of the colon – a new role for an old drug

Bibliography

• PARKS TG: Natural history of diverticular disease of the colon. Clin. Gastroenterol. (1974) 4:53–69.
   Google Scholar
• BOLES RS Jr, JORDAN SM: The clinical significance of diverticulosis. Gastroenterology (1958) 35:579–582.
   PubMedGoogle Scholar
• AYDIN HN, REMZI FH: Diverticulitis: when and how to operate? Digest. Liver Dis. (2004) 36:435–445.
   Google Scholar
• •A review evaluating the timing of surgical treatment for diverticular disease.
   Google Scholar
• BERMAN LG, BURDICK D, HEITZMAN ER, PRIOR JT: A critical reappraisal of sigmoid peridiverticulitis. Surg. Gyn. Obstet. (1968) 127:481–491.
   PubMedGoogle Scholar
• FLOCH M, BINA I: The natural history of diverticulitis — fact and theory. J. Clin. Gastroenterol (2004) 38\(Suppl. 1):S2–S7.
   Google Scholar
• ••An excellent review of the pathophysiologyand natural history of colonic diverticulitis.
   Google Scholar
• KOHLER L, SAUERLAND S, NEUGEBAUER E: Diagnosis and treatment of diverticular disease: result of a Consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg. Endosc. (1999) 13:430–436.
   PubMed Web of Science ®Google Scholar
• •Results of an European Consunsus Conference about the diagnosis and treatment of diverticular disease.
   Google Scholar
• TURSI A: Acute diverticulitis of the colon — current medical therapeutic management. Expert Opin. Pharmacother. (2004) 5:145–149.
   Google Scholar
• •A review of the current medical treatment of acute diverticulitis.
   Google Scholar
• SCHECHTER S, MULVEY J, EISENSTAT TE: Management of uncomplicated acute diverticulitis: results of a survey. Dis. Colon Rectum (1999) 42:470–476.
   PubMedGoogle Scholar
• •A wide multi-centre survey on behalf of the American Board of Colon and Rectal Surgeons (ASCRS) investigating the most popular antibiotics used for the treatment of uncomplicated diverticulitis.
   Google Scholar
• FERZOCO LB, RAPTOPOULOS V, SILEN W: Acute diverticulitis. N EngL J. Med. (1998) 338:1521–1526.
   PubMed Web of Science ®Google Scholar
• LAMANNA A, ORSI A: In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia (1984) 11:365–367.
   Google Scholar
• PAPI C, CIACO A, KOCH M, CAPURSO L: Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment. PharmacoL Ther. (1995) 9:33–39.
   PubMedGoogle Scholar
• •A well performed, double-blind, placebo-controlled study evaluating the effectiveness of rifaximin in the treatment of uncomplicated diverticulitis of the colon.
   Google Scholar
• LATELLA G, PIMPO MT, SOTTILI S et al.: Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int. J. Colorectal Dis. (2003) 18:55–62.
   PubMed Web of Science ®Google Scholar
• •The first study evaluating the role of rifaximin in maintaining remission of symptomatic uncomplicated diverticular disease throughout a long-term follow-up.
   Google Scholar
• HANAUER SB: Medical Therapy for ulcerative colitis 2004. Gastroenterology (2004) 126:1582–1592.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB: Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. PharmacoL Ther. (2003) 17:29–42.
   PubMed Web of Science ®Google Scholar
• ••An excellent review evaluating thepharmacokinetic profiles of all mesalazine formulations commercially available.
   Google Scholar
• ELIAKIM R, RACHMILEWITZ D: Potential mediators in inflammatory bowel disease. Gastroenterology Int. (1992) 5:48–56.
   Google Scholar
• GRISHAM MB: Oxidants and free radicals in inflammatoty bowel disease. Lancet (1994) 344:859–861.
   PubMed Web of Science ®Google Scholar
• WOOD AJJ: Inflammatory bowel disease. N EngL J. Med. (1996) 334:841–848.
   PubMedGoogle Scholar
• GONCALVES E, ALMEIDA LM, DINIS TC: Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: a synergistic interaction? Free Rad. Res. (1998) 29:53–66.
   Google Scholar
• RAMPTON DS: Diverticular colitis: diagnosis and management. Colorectal Disease (2001) 3:149–153.
   PubMedGoogle Scholar
• LUDEMAN L, SHEPERD NA: What is diverticular colitis? Pathology (2002) 34:568–572.
   PubMed Web of Science ®Google Scholar
• KELLY JK: Polypoid prolapsing mucosal folds in diverticular disease. Am. J. Surg. PathoL (1991) 15:871–878.
   PubMedGoogle Scholar
• SHEPERD NA: Colorectal submucosal mass lesions masquerading as chronic inflammatory bowel disease on mucosal biopsy. J. PathoL (1995) 175:119A.
   Google Scholar
• GUSLANDI M: Segmental colitis: so what? Eur. j Gastroenterol. Hepatol. (2003) 15:1–2.
   Google Scholar
• ROGLER G, ANDUS T: Cytokins in inflammatory bowel disease. World J. Surg (1998) 22:382–389.
   PubMed Web of Science ®Google Scholar
• IZZO AA, MASCOLO N, CAPASSO F: Nitric oxide as a modulator of intestinal water and electrolyte transport. Dig. Dis. Sci. (1998) 43:1605–1620.
   PubMed Web of Science ®Google Scholar
• TRESPI E, COLLA C, PANIZZA P et aL: Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 year follow-up results. Minerva Gastroenterol. DietoL (1999) 45:245–252.
   PubMedGoogle Scholar
• •The first paper describing the effectiveness of mesalazine in the treatment of symptomatic diverticular disease.
   Google Scholar
• GIOVANNI A, LEANDRO G, FANIGLIULO M et aL: Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Digest. Liver Dis. (2004) 36\(Suppl. 2):5189.
   Google Scholar
• BRANDIMARTE G, TURSI k Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med. Sci. Monit. (2004) 10:170–173.
   Google Scholar
• •The first study showing the effectiveness of mesalazine in treating symptomatic uncomplicated diverticulitis of the colon.
   Google Scholar
• TURSI A. BRANDIMARTE G, DAFFINÀ R: Long-term treatment with mesalazine and rifaximin versus rifaximin alone for the patients with recurrent attacks of acute diverticulitis of the colon. Digest. Liver. Dis. (2002) 34:510–515.
   Google Scholar
• ••A well conducted study showing for the first time the high effectiveness of the mesalazine/rifaximin association in the treatment and prevention of recurrent attacks of colonic diverticulitis throughout a 1-year follow-up.
   Google Scholar
• BASSOTTI G, CHISTOLINI F, MORELLI A: Pathophysiological aspect of diverticular disease of colon and role of large bowel motility. World J. Gastroenterol. (2003) 9:2140–2142.
   PubMed Web of Science ®Google Scholar
• TURSI A, BRANDIMARTE G, GIORGETTI GM, NASI G: Assessment of orocecal transit time in different localisation of Crohn's disease and its possibile influence on clinical response to therapy. Eur. Gastroenterol. HepatoL (2003) 15:69–74.
   PubMedGoogle Scholar
• SCHEIBER S, HAMLING J, ZEHNTER E et al.: Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut (1997) 40:761–766.
   PubMed Web of Science ®Google Scholar
• KRUIS W, SCHREIBER S, THEUER D et al.: Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut (2001) 49:738–739.
   Google Scholar
• LEVINE DS, RIFF DS, PRUITT R et al.: A randomized, double blind, dose response comparison of balsalazide (6.75 g), balsalazide (2.25 g) and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97:1398–1407.
   Google Scholar
• •A well conducted study showing the better effectiveness and tolerability of balsalazide rather then mesalazine in the treatment of mild-to-moderate ulcerative colitis.
   Google Scholar
• PRUITT R, HANSON J, SAFDI M et al.: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97:3078–3086.
   PubMed Web of Science ®Google Scholar
• SANDERS ME: Probiotics. Food TechnoL (1999) 53:67–77.
   Google Scholar
• GIACCARI S, TRONCI S, FALCONIERI M, FERRIERI A: Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. Eur. Rev. Med. PharmacoL Sci. (1993) 15:29–34.
   Google Scholar
• •The first paper describing the effectiveness of probiotics in post-diverticulitic stenoses.
   Google Scholar
• FRI P, ZAVORAL M: The effect of non- pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur. J. GastroenteroL HepatoL (2003) 15:313–315.
   PubMedGoogle Scholar
• •The first study evaluating the role of probiotics in improving the symptoms and prolonging the remission in patients with acute uncomplicated diverticulitis of the colon.
   Google Scholar
• DWIVEDI A, CHAHIN F, AGRAWAL S et al.: Laparoscopic colectomy versus open colectomy for sigmoid diverticular disease. Dis. Colon Rectum (2002) 45:1309–1314.
   PubMed Web of Science ®Google Scholar
• DUGAS B, MERCENIER A, LENOIR-WIJNKOOP I, ARNAUD C, DUGAS N, POSTAIRE E: Immunity and probiotics. Immunol. Today (1999) 20:387–390.
   PubMedGoogle Scholar
• BENGMARK S: Ecological control of thegastrointestinal tract. The role of probiotic flora. Gut (1998) 42:2–7.
   Google Scholar
• GIONCHETTI P, RIZZELLO F, CIFONE G et al.: In vivo effect of a highly concentrated probiotic on IL-10 pelvic pouch tissue levels. Gastroenterology (1999) 116:A723.
   Google Scholar
• GIONCHETTI P, AMADINI C, RIZZELLO F et al.: Probiotics — role in inflammatory bowel disease. Digest. Liver. Dis. (2002) 34\(Suppl. 2):S58–S62.
   Google Scholar
• •An interesting review about the role of probiotics in the treatment of IBD.
   Google Scholar